Patents by Inventor Peter Lawætz ANDERSEN

Peter Lawætz ANDERSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10786579
    Abstract: Disclosed herein is the use of Mycobacterium tuberculosis antigens for use in in vivo determination of the presence of Mtb infection in immunocompromised persons or persons co-infected with HIV and the for preparing a diagnostic reagent for skin testing (a skin test reagent) for robust assessment of the presence of Mtb infection infection in an individual wherein the individual is an immunocompromised person or a person co-infected with HIV.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: September 29, 2020
    Assignee: Statens Serum Institut
    Inventors: Henrik Aggerbeck, Peter Lawætz Andersen, Morten Ruhwald
  • Patent number: 10641770
    Abstract: The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic reagents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: May 5, 2020
    Assignee: Statens Serum Institut
    Inventors: Claus Aagaard, Søren Tetens Hoff, Ida Rosenkrands, Else Marie Agger, Peter Lawætz Andersen
  • Publication number: 20190151479
    Abstract: The present invention discloses the use of Mycobacterium tuberculosis antigens for use in in vivodetermination of the presence of Mtbinfection in immunocompromised persons or persons co-infected with HIVand the for preparing a diagnostic reagent for skin testing (a skin test reagent) for robust assessment of the presence of Mtbinfection in an individual wherein the individual is an immunocompromised person or a person co-infected with HIV.
    Type: Application
    Filed: November 15, 2016
    Publication date: May 23, 2019
    Applicant: Statens Serum Institut
    Inventors: Henrik Aggerbeck, Peter Lawætz Andersen, Morten Ruhwald
  • Patent number: 10004793
    Abstract: The present invention is directed to a fusion protein, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion protein, antigen cocktails and immunological compositions are based on proteins secreted by the ESAT-6 secretion system 1 (ESX-1) and are among the most immunodominant M. tuberculosis (MTB) antigens.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: June 26, 2018
    Assignee: Statens Serum Institut
    Inventors: Claus Aagaard, Ida Rosenkrands, Truc Thi Kim Thanh Hoang, Peter Lawaetz Andersen
  • Publication number: 20170043003
    Abstract: The present invention is directed to a fusion protein, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion protein, antigen cocktails and immunological compositions are based on proteins secreted by the ESAT-6 secretion system 1 (ESX-1) and are among the most immunodominant M. tuberculosis (MTB) antigens.
    Type: Application
    Filed: April 9, 2015
    Publication date: February 16, 2017
    Inventors: Claus Aagaard, Ida Rosenkrands, Truc Thi Kim Thanh Hoang, Peter Lawaetz Andersen
  • Publication number: 20170016897
    Abstract: The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic re agents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.
    Type: Application
    Filed: December 15, 2014
    Publication date: January 19, 2017
    Applicant: STATENS SERUM INSTITUT
    Inventors: Claus Aagaard, Søren Tetens Hoff, Ida Rosenkrands, Else Marie Agger, Peter Lawætz Andersen
  • Publication number: 20160228528
    Abstract: The present invention provides one or more immunogenic polypeptides for use in a preventive or therapeutic vaccine against latent or active infection in a human or animal caused by a Mycobacterium species, e.g. Mycobacterium avium subsp. paratuberculosis. Furthermore a single or multi-phase vaccine comprising the one or more immunogenic polypeptides is provided for administration for the prevention or treatment of infection with a Mycobacterium species, e.g. Mycobacterium avium subsp. paratuberculosis. Additionally, nucleic acid vaccines, capable of in vivo expression of the multi-phase vaccine comprising the one or more immunogenic polypeptides, is provided for prevention or treatment of infection with a Mycobacterium species, e.g. Mycobacterium avium subsp. paratuberculosis.
    Type: Application
    Filed: January 28, 2014
    Publication date: August 11, 2016
    Inventors: Gregers JUNGERSEN, Aneesh THAKUR, Claus AAGAARD, Peter Lawætz ANDERSEN, Heidi MIKKELSEN